1. Home
  2. SPRO vs TKNO Comparison

SPRO vs TKNO Comparison

Compare SPRO & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.20

Market Cap

156.3M

Sector

Health Care

ML Signal

HOLD

Logo Alpha Teknova Inc.

TKNO

Alpha Teknova Inc.

HOLD

Current Price

$5.07

Market Cap

138.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRO
TKNO
Founded
2013
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
156.3M
138.1M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
SPRO
TKNO
Price
$2.20
$5.07
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.6M
208.7K
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
111.81
43.86
EPS
N/A
N/A
Revenue
$66,802,000.00
$40,520,000.00
Revenue This Year
N/A
$8.27
Revenue Next Year
$300.00
$13.13
P/E Ratio
N/A
N/A
Revenue Growth
39.24
7.35
52 Week Low
$1.80
$1.91
52 Week High
$3.09
$6.68

Technical Indicators

Market Signals
Indicator
SPRO
TKNO
Relative Strength Index (RSI) 36.21 62.72
Support Level $2.19 $4.79
Resistance Level $2.47 $5.84
Average True Range (ATR) 0.26 0.49
MACD -0.07 -0.03
Stochastic Oscillator 22.29 60.00

Price Performance

Historical Comparison
SPRO
TKNO

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About TKNO Alpha Teknova Inc.

Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.

Share on Social Networks: